We are happy to announce that our beloved OYSTA project has been awarded with the prestigious UX Design Award.
Thanks to the outstanding work of our partner Star, a global technology consultancy, which takes care of OYSTA Digital Service, the companion to our OYSTA Dosage Manager. In recognition of the exceptional design and innovation behind the OYSTA Digital Service, this digital solution was honored in the product category for its outstanding ease of use and intuitive way of interacting and tracking treatment.
With OYSTA, we aim to improve the lives of people with ADHD and other conditions through individualized dosing, safe medication management, and treatment support. OYSTA enables healthcare providers (HCP), patients, caregivers, and teachers manage ADHD in children effectively, offering medication adherence support, educational information, data analysis, reporting and management.
OYSTA is a cooperation between Tiefenbacher Group and OnDosis.
Together we want to revolutionize how patients take their medicines by combining pharmaceuticals and e-health technology so that every individual gets precisely the right dose of the medicine they need in a simpler, more comfortable way.
This milestone reflects the teams’ dedication to creating a product that not only meets medical and technical standards but also prioritizes the needs of patients and healthcare providers ensuring the solution is both effective and accessible. The recognition underscores the impact of the collaboration on improving patient outcomes and sets a high standard for future digital health solutions.
For more information about OYSTA, visit oysta-health.com, and explore the work of our partner Star at star.global.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
